AstraZeneca drug cocktail succeeds in late-stage study to treat COVID-19

13 Sept 19:32 Key points summarised by AI

AstraZeneca has requested U.S. emergency approval for its antibody cocktail, AZD7442, as a preventative shot against COVID-19.
Unlike vaccines, AZD7442 provides lab-made antibodies designed to offer long-lasting protection (months to a year), particularly for immunocompromised individuals who may not respond well to vaccines.
Late-stage trial data included in the FDA filing demonstrated that the drug reduced the risk of developing any COVID-19 symptoms by 77%.
A U.S. authorization for AZD7442 would be a significant win for AstraZeneca, which is currently engaged in supply negotiations with the United States and other governments.

Sihasak urges Thais in Europe to stay alert as protests spread

Yesterday 12:06 Key points summarised by AI

Thai Foreign Minister Sihasak Phuangketkeow advises Thai nationals in Europe to avoid protest areas and reconsider non-essential travel, citing widespread unrest in countries like France, Italy, and Spain.
The warning comes as demonstrations escalate, with some turning violent, prompting concerns for safety and leading to an emergency Cabinet meeting in Italy and a proposed postponement of diplomatic talks.
Thai embassies and the Department of Consular Affairs issue advisories, urging citizens to monitor local developments, follow official announcements, and register their travel details for assistance, while emphasizing that no Thais have been directly affected yet.